Abstract
Serum tissue polypeptide antigen, (TPA), carcinoembryonic antigen (CEA), calcitonin (CT) and thyroglobulin (Tg) have been measured by specific radioimmunoassays in 174 patients with various types of thyroid cancer previously submitted to thyroidectomy. Elevated serum TPA concentrations were found in 12 of 13 patients with local invasion or distant metastases from undifferentiated thyroid cancer or thyroid lymphosarcoma, while serum Tg and CEA values were normal or undetectable. In 123 patients with well differentiated thyroid cancer serum TPA was usually normal regardless of the presence or absence of functioning metastases. On the contrary, 14 of 15 patients with “dedifferentiated” metastases from previously differentiated thyroid cancer had elevated serum TPA values, while serum CEA was normal and serum Tg variable. Serum CT was confirmed as the most sensitive marker of metastatic medullary thyroid carcinoma, but elevated serum TPA values were also found in most of these cases. The present data indicate that serum TPA provides a new humoral marker in the follow-up of undifferentiated and “dedifferentiated” thyroid carcinoma and may also be usefully employed as an additional marker for medullary thyroid carcinoma.
References
Van Herle A., Vassart G., Dumont J.E. Control of thyroglobulin synthesis and secretion (second of two part). N. Engl. J. Med. 307: 307, 1979.
Pacini F., Pinchera A., Giani C., Grasso L., Doveri F., Baschieri L. Serum thyroglobulin in thyroid carcinoma and other thyroid disorders. J. Endocrinol. Invest. 3: 283, 1980.
Hazard J.B. The C-cells(parafollicular cells) of the thyroid gland and medullary thyroid carcinoma. Am. J. Pathol. 88: 214, 1977.
Ishikawa N., Hamada S. Association of medullary carcinoma of the thyroid with carcinoembryonic antigen. Br. J. Cancer 34: 111, 1976.
DeLellis R.A., Rule A.H., Spiler I., Nathanson L., Tashijian A.H. Jr., Wolfe H.J. Calcitonin and carcinoembryonic antigen as tumor markes in medullary thyroid carcinoma. Am. J. Clin. Pathol. 70: 587, 1978.
Calmettes C., Moukhttar M.S., Milhaud G. Plasma carcinoembryonic antigen versus plasma calcitonin in the diagnosis of the medullary carcinoma of the thyroid. Cancer Immunol. Imunother. 4: 251, 1978.
Burtin P., Calmettes C., Fondaneche M.C. CEA and non-specific cross-reacting antigen (NCA) in medullary carcinoma of the thyroid.
Beatty J.D., and Terz J.J. Value of carcinoembryonic antigen in clinical medicine. In: Ariel I.M. (Ed.), Progress in Clinical Cancer, vol. VIII, Gr-Stratton New York, 1982, p. 9.
Baschieri L., Giani C., Mariotti S., Pacini F., Busnardo B., Girelli M.E., Pinchera A. Markers of thyroid tumors. In: Colnaghi M.I., Buraggi G.L., Ghione M. (Eds.), Markers for diagnosis and monitoring of human cancer. Academy Press, New York, 1982, p. 259.
Pacini F., Pinchera A., Giani C., Grasso L., Baschieri L. Serum thyroglobulin concentration and 131-l whole body scan in the diagnosis of metastases from differentiated thyroid carcinoma (after thyroidectomy). Clin. Endocrinol. (Oxf.) 13: 207, 1980.
Bjorklund B., Bjorklund V. Antigenicity of pooled human malignant and normal tissues by cyto-immunological technique: presence of an insoluble, hdeatlabile tumor antigen. Int. Arch. All. Appl. Immun. 10: 153, 1957.
Bjorklund B., Bjorklund V. Specificity and basis of the tissue polypeptide antigen. Cancer Detect. Prevent. 6: 41, 1983.
Lüthgens M., Schlegel G. Combined use of carcino-embryonic antigen and tissue polypeptide antigen in oncologic therapy and surveillance. Cancer Detect. Prevent. 6: 51, 1983.
Wiklund B., Luning B. Bjorklund B. Chemical studies of tissue polypeptide antigen (TPA). III. On the nature of the antigenic determinant of TPA subfraction B1. Acta Chem. Scand. 35: 325, 1981.
Bjorklund B. Tissue polipeptyde antigen (TPA): biology, biochemistry, improved assay metodology, clinical significance in cancer and other conditions and future outlook. Antib. Chemioter. 2: 16, 1978.
Menendez-Botet C.I., Oettgen H.F., Pinshy C.M., Schwartz M.K. A preliminary evaluation of tissue polypeptide antigen in serum or urine (or both) of patients with cancer of benign neoplasm. Clin. Chem. 24: 868, 1978.
Mross K., Mross B., Wolfrum D.I., Rauschecker H. Determination of TPA in breast cancer and controls. Klin. Wochenschr. 61: 461, 1983.
Schlegel G., Luthgens M., Eklund G., Bjorklund B. Correlation between activity in brast cancer and CEA, TPA and eighteen common laboratory procedure and improvement by combined use of CEA and TPA. Tumor Diagnostik 2: 6, 1981.
Mariotti S., Cupini C., Giani C., Lari R., Rolleri E., Falcao A., Marchisio M., Pinchera A. Evaluation of a solid phase immunoradiometric assay (IRMA) for serum thyroglobulin: effect of antithyroglobul-in antibody. Clin. Chim. Acta 123: 347, 1982.
Luthgens M., Schlegel G.T. Verlaufskontrolle mit Tissue Polypeptide Antigen und Carcinoembryonalem Antigen in der Radiosonkologischen Nachsorge and Therapie. Tumor Diagnostik 2: 179, 1981.
Nemoto T., Constantine R., Chu T.M. Human tissue polypeptide antigen in brast cancer. J.N.C.I. 63: 1347, 1979.
Van Herle A.J., Uller R.P. Evaluated serum thyroglobulin: a marker of metastases in a differentiated thyroid carcinoma. J. Clin. Invest. 56: 272, 1975.
Harada T., Ito K., Shimaoka K., Hosoda Y., Yakumaru K. Fatal thyroid carcinoma. Anaplastic transformation of a adenocarcinoma. Cancer 39: 2588, 1977.
Lundstrom R., Bjorklund B., Eklund G. A tissue derived polypeptide antigen: its relation to cancer and its temporary occurrence in certain infectious diseases. In: B. Bjorklund (Ed.), Immunological tecniques for detection of cancer Bonniers, Stockolm, 1973, p. 243.
Ruibal A., Clotet B., Pigrau G., Duran-Bellido P., Fraile M., Roca I. Tissue polyptide antigen in autoimmune disease. Tumor Diagnostik 3: 40, 1982.
Author information
Authors and Affiliations
Additional information
This work has been supported in part by a grant from C.N.R. (Roma, Italy) Progetto Finalizzato Oncologia, Sottoprogetto 10.
Rights and permissions
About this article
Cite this article
Martino, E., Bambini, G., Aghini-Lombardi, F. et al. Serum tissue polypeptide antigen (TPA) in thyroid cancer. J Endocrinol Invest 7, 249–252 (1984). https://doi.org/10.1007/BF03348433
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03348433